About DrugPrice

Why Medicare Part D spending data deserves a dedicated home

The Centers for Medicare and Medicaid Services (CMS) publishes the Medicare Part D Drug Spending dashboard annually — every drug Medicare paid for, the total payments, the number of beneficiaries, the cost per claim, and the year-over-year change. The dataset is the most comprehensive public record of U.S. prescription-drug economics. The official CMS interface is built for analysts and journalists; the same data, presented for a patient or caregiver trying to understand what a specific prescription costs, requires substantially more navigation than most people are willing to do.

DrugPrice is built to make the CMS data accessible. Every drug page shows total Medicare Part D spending, beneficiary count, average per-claim cost, and the multi-year price trend. Every manufacturer page rolls up the company’s full Medicare drug portfolio. The data is the CMS data that has always been public; the value the site adds is the navigation that makes a specific drug or company answerable in seconds rather than after a Census-style data download.

How the pipeline pulls CMS data

The pipeline pulls the annual CMS Medicare Part D spending file when it publishes — typically mid-year, with the prior calendar year’s spending. The pull touches every drug in the file (thousands), every manufacturer, and aggregates into the per-drug, per-manufacturer, and per-class pages. The FDA Orange Book provides the cross-reference for generic alternatives where they exist.

The per-drug page shows total Medicare Part D spending and beneficiary count to give the dollar-scale and patient-scale picture, plus the per-claim average to make the typical-prescription-cost answer obvious. The methodology page describes every input series with the source URL.

Where Medicare drug data has caveats

Three caveats. First, Part D spending reflects plan-reimbursed amounts, not rebated net prices. Pharmaceutical manufacturers pay confidential rebates to plan sponsors that can run 20-40 percent of the headline price; the actual manufacturer revenue is materially lower than the Part D file shows. Public data does not capture the rebate structure, and CMS data therefore overstates true manufacturer revenue. The methodology page on this site documents every dataset, every refresh cadence, and every limitation in detail so readers can trace any numeric value on the site back to the underlying federal source. We treat that traceability as a hard requirement for any data product that asks readers to make real-world decisions on its output.

Second, the Part D file excludes Medicare Part B drugs (clinician-administered) and excludes Medicaid drug spending, which uses a different rebate structure. Drugs filled outside Medicare entirely — commercial insurance, cash-pay generics — are not in this dataset.

Third, a beneficiary count is not the same as a patient count for the calendar year because Medicare patients can switch drugs or fill different drugs in the same class. The per-drug beneficiary count is the right scale for that specific drug; cross-drug comparisons require care to avoid double-counting.